Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Teruo Tsuchiya is active.

Publication


Featured researches published by Teruo Tsuchiya.


Chemical Research in Toxicology | 2011

The Pivotal Role of Intracellular Calcium in Oxaliplatin-Induced Inhibition of Neurite Outgrowth but Not Cell Death in Differentiated PC12 Cells

Miki Takeshita; Yoshiko Banno; Mitsuhiro Nakamura; Mayuko Otsuka; Hitomi Teramachi; Teruo Tsuchiya; Yoshinori Itoh

The antineoplastic efficacy of oxaliplatin, a widely used anticancer drug, is restricted by its adverse effects such as peripheral neuropathy. Infusing a combination of calcium gluconate and magnesium sulfate (Ca/Mg) suppresses the acute neurotoxic side effects of oxaliplatin, although the mechanism is unclear. To elucidate the molecular mechanisms of oxaliplatin-induced neurotoxicity and the effects of Ca/Mg against this toxicity, we examined the effect of Ca/Mg on oxaliplatin-induced inhibition of neurite outgrowth in PC12 cells, a commonly used neuronal cell model. Oxaliplatin and oxalate suppressed nerve growth factor (NGF)-induced neurite outgrowth and reduced the NGF-mediated increase in the intracellular calcium concentration [Ca(2+)](i). A calcium-chelating agent, BAPTA/AM, also exhibited similar inhibitory effects on neurite outgrowth and [Ca(2+)](i). The addition of Ca/Mg attenuated these inhibitions induced by oxaliplatin and oxalate. The NGF-induced upregulation of growth-associated protein-43 (GAP-43) was suppressed by oxaliplatin and oxalate. Oxaliplatin, but not oxalate, suppressed NGF-stimulated extracellular signal-regulated kinase activation, and this inhibition was not affected by Ca/Mg. Ca/Mg did not modify the oxaliplatin-induced loss of cell viability or apoptosis in PC12 or HCT-116 cells, a human colorectal cancer cell line. These results suggest that the inhibition of neurite outgrowth but not tumor cell death induced by oxaliplatin is partly associated with reductions in [Ca(2+)](i) and GAP-43 expression, and this inhibition was suppressed by the addition of Ca/Mg. Therefore, it may be assumed that Ca/Mg is useful for protecting against oxaliplatin-induced neurotoxicity without reducing the antitumor activity of oxaliplatin.


Biological & Pharmaceutical Bulletin | 2015

Analysis of the Interaction between Clopidogrel, Aspirin, and Proton Pump Inhibitors Using the FDA Adverse Event Reporting System Database

Yukiya Suzuki; Honami Suzuki; Ryogo Umetsu; Hiroaki Uranishi; Junko Abe; Yuri Nishibata; Yasuaki Sekiya; Nobuteru Miyamura; Hideaki Hara; Teruo Tsuchiya; Yasutomi Kinosada; Mitsuhiro Nakamura

Clopidogrel is an antiplatelet agent widely used in combination with aspirin to limit the occurrence of cardiovascular (embolic/thrombotic) events. Consensus guidelines recommend proton pump inhibitors (PPIs) as a gastrointestinal (GI) prophylactic measure for all patients receiving dual antiplatelet therapy with clopidogrel and aspirin. The objective of this study was to analyze the effect of the simultaneous use of clopidogrel, aspirin, and PPIs on hemorrhagic and embolic/thrombotic events using the U.S. Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS) database. Reports of hemorrhagic and embolic/thrombotic events between 2004 and 2013 were analyzed with a reporting odds ratio (ROR) algorithm and logistic regression methods. The Medical Dictionary for Regulatory Activities Preferred Terms was used to identify such events. Regarding hemorrhagic events, the adjusted RORs of the concomitant use of aspirin and clopidogrel and those of PPIs prescribed with aspirin and clopidogrel were 4.40 (95% confidence interval [CI], 4.02-4.81) and 3.40 (95% CI, 2.84-4.06), respectively. For embolic/thrombotic events, the adjusted RORs of the concomitant use of aspirin and clopidogrel and those of PPIs prescribed with aspirin and clopidogrel were 2.37 (95% CI, 2.16-2.59) and 2.38 (95% CI, 2.00-2.84), respectively. Among patients included in the FAERS database, the concurrent use of aspirin and clopidogrel with PPIs reduced the adjusted ROR of GI hemorrhagic events. PPIs had little influence on the adjusted ROR of embolic/thrombotic events. These results support the use of PPIs as a preventive measure against GI hemorrhagic events for patients receiving clopidogrel and aspirin.


PLOS ONE | 2015

The Impact of Outpatient Chemotherapy-Related Adverse Events on the Quality of Life of Breast Cancer Patients

Tomoya Tachi; Hitomi Teramachi; Kazuhide Tanaka; Shoko Asano; Tomohiro Osawa; Azusa Kawashima; Masahiro Yasuda; Takashi Mizui; Takumi Nakada; Yoshihiro Noguchi; Teruo Tsuchiya; Chitoshi Goto

The objective of our study was to clarify the impact of adverse events associated with the initial course of outpatient chemotherapy on the quality of life of breast cancer patients. We conducted a survey to assess the quality of life in 48 breast cancer patients before and after receiving their first course of outpatient chemotherapy at Gifu Municipal Hospital. Patients completed the European Quality of Life 5 Dimensions and Quality of Life Questionnaire for Cancer Patients Treated with Anticancer Drugs before and after 1 course of outpatient chemotherapy. European Quality of Life 5 Dimensions utility value and Quality of Life Questionnaire for Cancer Patients Treated with Anticancer Drugs total score decreased significantly after chemotherapy (p<0.001 and p = 0.018, respectively). The mean scores for the activity, physical condition, and psychological condition subscales of the Quality of Life Questionnaire for Cancer Patients Treated with Anticancer Drugs decreased significantly after chemotherapy (p = 0.003, p<0.001, and p = 0.032, respectively), whereas the social relationships score increased significantly (p<0.001). Furthermore, in the evaluation of quality of life according to individual adverse events, the decrease in quality of life after chemotherapy in terms of the European Quality of Life 5 Dimensions utility value and the Quality of Life Questionnaire for Cancer Patients Treated with Anticancer Drugs total score was greater in anorexic patients than in non-anorexic patients (p = 0.009 and p<0.001, respectively). This suggests that anorexia greatly reduces quality of life. Our findings reveal that anticancer drug-related adverse events, particularly anorexia, reduce overall quality of life following the first course of outpatient chemotherapy in current breast cancer patients. These findings are extremely useful and important in understanding the impact of anticancer drug-related adverse events on quality of life.


European Journal of Clinical Nutrition | 2015

Hyponatremia and hypokalemia as risk factors for falls

Tomoya Tachi; T Yokoi; Chitoshi Goto; Umeda M; Yoshihiro Noguchi; Masahiro Yasuda; M Minamitani; Takashi Mizui; Teruo Tsuchiya; Hitomi Teramachi

Background/objectives:Fall accidents may reduce an individual’s quality of life and ability to perform the activities of daily life, and may delay recovery from illness. Consequently, medical institutions need to take measures to prevent falls. There are various risk factors for falls, including advanced age, illness and medication effects. Although hyponatremia and hypokalemia have been reported to increase the rate of falls, how they affect falls is not fully understood.Subjects/methods:We retrospectively examined 2948 patients, ⩾18 years old who had been hospitalized for ⩾3 days at Gifu (Japan) Municipal Hospital between May 2012 and April 2013 to determine the effects of hyponatremia and hypokalemia on the risk of falls. After the patients had been divided into fall and non-fall groups, their data were subjected to univariate and multiple regression analysis to identify significant differences.Results:The univariate analysis results revealed significant differences between the groups in terms of age (⩾65 years); the presence of hyponatremia, hypokalemia, central nervous system disease, cardiovascular disease and/or peripheral nerve/muscular disease; intake of medications that increase the risk of falls; and increased sedative dosage. The multivariate analysis results revealed significant differences between the groups in terms of the presence of hyponatremia (odds ratio (OR), 1.751; 95% confidence interval (CI), 1.020–3.005), hypokalemia (OR, 2.209; 95% CI, 1.280–3.813), central nervous system disease (OR, 2.492; 95% CI, 1.629–3.814) and/or age ⩾65 years (OR, 2.180; 95% CI, 1.242–3.826).Conclusions:The results indicated that the presence of hyponatremia or hypokalemia increases the risk of falls.


Journal of Chromatography B | 2011

Direct-injection HPLC method of measuring micafungin in human plasma using a novel hydrophobic/hydrophilic hybrid ODS column.

Hiroaki Uranishi; Mitsuhiro Nakamura; Hiroki Nakamura; Yukari Ikeda; Mayuko Otsuka; Zenichiro Kato; Teruo Tsuchiya

A direct-injection HPLC-based method has been developed for determining amounts of micafungin in human plasma using a novel hydrophobic/hydrophilic hybrid ODS column. The method is easy to perform and requires only 10 μL of a filtered plasma sample. The chromatographic separations were carried out with a gradient mode. The fluorescence detection wavelengths of excitation and emission were set at 273 nm and 464 nm, respectively. Retention times for micafungin and IS were 22.4 and 23.7 min, respectively. Micafungin and FR195743 (IS) peaks were completely separated with little tailing, and no interference was observed. The calibration curve of micafungin showed good linearity in the range of 0.5-20.0 μg/mL (r(2)=1.00). The intra-day accuracy ranged from -4.5 to 5.3%. The inter-day accuracy ranged from -9.8 to 1.5%. The precisions were less than 10%. This method is useful for the determination of micafungin in human plasma.


Carbohydrate Research | 1989

Preparation and mass-spectral analysis of O-hydroxy-ethyl derivatives of d-glucose

Katsuyuki Nagai; Atsuko Honda; Tadashi Kiho; Shigeo Ukai; Teruo Tsuchiya

Various hydroxyethyl ethers of d-glucose have been prepared in good yield by treating d-glucose derivatives with 2-bromoethyl tetrahydropyranyl ether in the presence of sodium hydride. The derived O-(hydroxyethyl)-d-glucitol acetates exhibited characteristic mass-spectral fragments. The furanose and pyranose forms of 1,2-O-ethylene-d-glucose derived from 2-O-(2-hydroxyethyl)-d-glucose were identified by mass-spectral analysis.


Sage Open Medicine | 2014

Influence of angiotensin II receptor blocker combination tablet prescription on drug number and cost.

Hitomi Teramachi; Tatsuya Takahashi; Tomoya Tachi; Yoshihiro Noguchi; Hiroyuki Nagasawa; Yoko Ino; Takashi Mizui; Chitoshi Goto; Teruo Tsuchiya

Objectives: Combination therapy using an angiotensin II receptor blocker is expected to promote medication adherence and alleviate economic burden among patients by reducing the number of drugs taken, and thereby to lower associated medical costs. In the present retrospective study, we conducted a survey on the use of angiotensin II receptor blocker–containing combination tablets as anti-hypertensive drugs, in particular angiotensin II receptor blocker/diuretic and angiotensin II receptor blocker/calcium channel blocker combinations, in order to investigate the number of prescribed drugs and drug cost. Methods: We performed a retrospective study of patients who visited the outpatient clinic of GifuMunicipalHospital and received anti-hypertensive agents between June 2006 and December 2011. Results: No reductions in the number of prescribed drugs or drug cost were seen following a change in prescription to an angiotensin II receptor blocker/diuretic. Patients receiving an angiotensin II receptor blocker/calcium channel blocker had a significant reduction in the number of prescribed drugs and a slight decrease in drug cost. Conclusion: In this study, a reduction in the number of prescribed drugs and a decrease in economic burden were not observed after prescription of angiotensin II receptor blocker–containing combination tablets. In order to assess the usefulness of angiotensin II receptor blocker combination tablets, further studies are necessary to investigate their hypotensive effects, safety profile, and other factors.


Journal of Pharmacy Practice | 2013

Pharmaceutical Care for Patients Undergoing S-1 Plus Cisplatin Therapy for Unresectable Recurrent Gastric Cancer

Michio Kimura; Eiseki Usami; Tomoaki Yoshimura; Tadashi Yasuda; Yuji Kaneoka; Hitomi Teramachi; Tadashi Sugiyama; Teruo Tsuchiya

We examined the adverse gastrointestinal events associated with tegafur/gimeracil/oteracil potassium (S-1) plus cisplatin therapy for unresectable recurrent gastric cancer and risk factors for discontinuing therapy due to adverse events. A total of 65 subjects who had received S-1 plus cisplatin therapy for gastric cancer at Ogaki Municipal Hospital were examined. We found that the risk factors for discontinuation of the therapy due to adverse events were serum albumin (Alb) level less than 3.5 g/dL (odds ratio [OR]: 321.14, P = .0015), creatinine clearance (CrCl) rate less than 78 mL/min (OR: 35.23, P = .0123), and performance status (PS) more than 1 (OR:12.62, P = .0243). Moreover, grade 3 or 4 nonhematological toxicities (including malaise and anorexia) were significantly higher in subjects with Alb less than 3.5 g/dL and CrCl less than 78 mL/min (P < .01). In conclusion, we should pay attention to the safety and continuity of S-1 plus cisplatin therapy in cases where the Alb level is <3.5 g/dL, CrCl level is <78 mL/min, and PS level is >1. Pharmacists should consider reducing the treatment dosage and providing nutritional support in such cases.


Journal of Pharmaceutical Health Care and Sciences | 2018

Analyses of non-benzodiazepine-induced adverse events and prognosis in elderly patients based on the Japanese adverse drug event report database

Yoshihiro Noguchi; Anri Ueno; Hayato Katsuno; Manami Otsubo; Aki Yoshida; Yuta Kanematsu; Ikuto Sugita; Tomoya Tachi; Teruo Tsuchiya; Hitomi Teramachi

BackgroundThe contents of the guidelines for the use of non-benzodiazepines (Z-drugs) differ slightly between THE JAPANESE SOCIETY OF SLEEP RESEARCH and THE JAPAN GERIATRIC SOCIETY, and the recommended directions are conflicting. Therefore, we analyzed the use of the Japanese Adverse Drug Event Report database (JADER) for identifying adverse events (AEs) caused by Z-drugs and clarifying their occurrence trend and prognosis.MethodsThe signal value for comparison was calculated by using the proportional reporting ratio (PRR) and chi-squared test (χ2) results of data of elderly and non-elderly patients. Among AEs for which signals were detected in the elderly, we determined that those with lower signal values for non-elderly patients that were half the signal value of the elderly should be used with particular caution in the elderly. We also compared the prognoses.ResultsThe AEs with > 1 risk ratio (RR) in elderly and non-elderly patients were regarded as those that should be noted in the prognosis of AEs in elderly patients. Furthermore, 28 AEs were detected in elderly patients’ signals. In this study, in addition to movement disorders such as “falls” and “bone fractures,” identified by two academic societies, signal characteristics of the elderly were obtained for psychiatric disorders and eye disorders.ConclusionsThere was no difference in prognosis, but these disorders could reduce the quality of life of patients. Therefore, we consider that in prescribing appropriate drug therapy for insomnia, attention should be paid to the occurrence of the AEs caused by the Z-drugs revealed by this study and the guidelines.


Frontiers in Pharmacology | 2018

The Effect of Quality of Life on Medication Compliance Among Dialysis Patients

Hiroyuki Nagasawa; Tomoya Tachi; Ikuto Sugita; Hiroki Esaki; Aki Yoshida; Yuta Kanematsu; Yoshihiro Noguchi; Yukio Kobayashi; Etsuko Ichikawa; Teruo Tsuchiya; Hitomi Teramachi

Dialysis treatment is known to lead to reduced quality of life (QOL) among patients. This decreased QOL is believed to influence medication compliance, although this effect has not yet been clarified. In this study, we investigated whether decreased QOL due to dialysis treatment does in fact influence medication compliance. Participants were 92 patients who self-managed their medication and were receiving dialysis treatment at Secomedic Hospital or Chiba Central Medical Center. We surveyed their age, sex, dialysis period, and medication management situation, and administered the EQ-5D and Kidney Disease Quality of Life Instrument–Short Form. A multiple logistic regression analysis with medication compliance as the dependent variable and QOL as the independent variable was conducted. The recovery rate and effective response rate were both 100%. The results indicated that patients with good sleep QOL (mean or above) had higher odds of medication compliance (odds ratio, 3.36; 95% confidence interval, 1.26–8.96; P = 0.016). Therefore, improving the quality of sleep of dialysis patients might help to improve their medication compliance.

Collaboration


Dive into the Teruo Tsuchiya's collaboration.

Top Co-Authors

Avatar

Hitomi Teramachi

Gifu Pharmaceutical University

View shared research outputs
Top Co-Authors

Avatar

Tomoya Tachi

Gifu Pharmaceutical University

View shared research outputs
Top Co-Authors

Avatar

Yoshihiro Noguchi

Gifu Pharmaceutical University

View shared research outputs
Top Co-Authors

Avatar

Mitsuhiro Nakamura

Gifu Pharmaceutical University

View shared research outputs
Top Co-Authors

Avatar

Shigeo Ukai

Gifu Pharmaceutical University

View shared research outputs
Top Co-Authors

Avatar

Tadashi Kiho

Gifu Pharmaceutical University

View shared research outputs
Top Co-Authors

Avatar

Eiji Takashima

Gifu Pharmaceutical University

View shared research outputs
Top Co-Authors

Avatar

Masafumi Kubota

Gifu Pharmaceutical University

View shared research outputs
Top Co-Authors

Avatar

Tadashi Sugiyama

Gifu Pharmaceutical University

View shared research outputs
Top Co-Authors

Avatar

Aki Yoshida

Gifu Pharmaceutical University

View shared research outputs
Researchain Logo
Decentralizing Knowledge